A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy

Susan Callaghan; Mikhail A. Filatov; Huguette Savoie; Ross W. Boyle; Mathias O. Senge

doi:10.1117/12.2525246

A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy

Susan Callaghan
, Mikhail A. Filatov
, Huguette Savoie
, Ross W. Boyle
, Mathias O. Senge

School of Chemical and BioPharmaceutical Science

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

Over the past four years we have developed BODIPY dyads capable of triplet state generation from charge transfer states generated by photoinduced electron transfer. In the current work we identify a lead compound for application in photodynamic therapy. This system is composed of a phenylanthracene electron donor unit and a dimethyl-substituted BODIPY acceptor unit. We have demonstrated that this compound, in sub-micromolar concentrations, can effectively generate singlet oxygen in polar solvents and induce cytotoxicity in human breast cancer cells (MDA-MB-468) when exposed to light. The photophysical properties of these compounds are chemically tunable and thus open the door not only to a new class of photodynamic therapy photosensitizers, but also agents for triplet-triplet annihilation up-conversion applications.

Original language	English
Title of host publication	17th International Photodynamic Association World Congress
Editors	Tayyaba Hasan
Publisher	SPIE
ISBN (Electronic)	9781510628335
DOIs	https://doi.org/10.1117/12.2525246
Publication status	Published - 2019
Event	17th International Photodynamic Association World Congress 2019 - Cambridge, United States Duration: 28 Jun 2019 → 4 Jul 2019

Publication series

Name	Proceedings of SPIE - The International Society for Optical Engineering
Volume	11070
ISSN (Print)	0277-786X
ISSN (Electronic)	1996-756X

Conference

Conference	17th International Photodynamic Association World Congress 2019
Country/Territory	United States
City	Cambridge
Period	28/06/19 → 4/07/19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BODIPY
Photodynamic Therapy
Photosensitizer
Singlet Oxygen
Triplet State

Access to Document

10.1117/12.2525246

Cite this

Callaghan, S., Filatov, M. A., Savoie, H., Boyle, R. W., & Senge, M. O. (2019). A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy. In T. Hasan (Ed.), 17th International Photodynamic Association World Congress Article 110709I (Proceedings of SPIE - The International Society for Optical Engineering; Vol. 11070). SPIE. https://doi.org/10.1117/12.2525246

@inproceedings{d9efa7fe678f40babcfd466089b0237a,

title = "A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy",

abstract = "Over the past four years we have developed BODIPY dyads capable of triplet state generation from charge transfer states generated by photoinduced electron transfer. In the current work we identify a lead compound for application in photodynamic therapy. This system is composed of a phenylanthracene electron donor unit and a dimethyl-substituted BODIPY acceptor unit. We have demonstrated that this compound, in sub-micromolar concentrations, can effectively generate singlet oxygen in polar solvents and induce cytotoxicity in human breast cancer cells (MDA-MB-468) when exposed to light. The photophysical properties of these compounds are chemically tunable and thus open the door not only to a new class of photodynamic therapy photosensitizers, but also agents for triplet-triplet annihilation up-conversion applications.",

keywords = "BODIPY, Photodynamic Therapy, Photosensitizer, Singlet Oxygen, Triplet State",

author = "Susan Callaghan and Filatov, \{Mikhail A.\} and Huguette Savoie and Boyle, \{Ross W.\} and Senge, \{Mathias O.\}",

note = "Publisher Copyright: {\textcopyright} 2019 SPIE.; 17th International Photodynamic Association World Congress 2019 ; Conference date: 28-06-2019 Through 04-07-2019",

year = "2019",

doi = "10.1117/12.2525246",

language = "English",

series = "Proceedings of SPIE - The International Society for Optical Engineering",

publisher = "SPIE",

editor = "Tayyaba Hasan",

booktitle = "17th International Photodynamic Association World Congress",

address = "United States",

}

Callaghan, S, Filatov, MA, Savoie, H, Boyle, RW & Senge, MO 2019, A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy. in T Hasan (ed.), 17th International Photodynamic Association World Congress., 110709I, Proceedings of SPIE - The International Society for Optical Engineering, vol. 11070, SPIE, 17th International Photodynamic Association World Congress 2019, Cambridge, United States, 28/06/19. https://doi.org/10.1117/12.2525246

A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy. / Callaghan, Susan; Filatov, Mikhail A.; Savoie, Huguette et al.
17th International Photodynamic Association World Congress. ed. / Tayyaba Hasan. SPIE, 2019. 110709I (Proceedings of SPIE - The International Society for Optical Engineering; Vol. 11070).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy

AU - Callaghan, Susan

AU - Filatov, Mikhail A.

AU - Savoie, Huguette

AU - Boyle, Ross W.

AU - Senge, Mathias O.

PY - 2019

Y1 - 2019

N2 - Over the past four years we have developed BODIPY dyads capable of triplet state generation from charge transfer states generated by photoinduced electron transfer. In the current work we identify a lead compound for application in photodynamic therapy. This system is composed of a phenylanthracene electron donor unit and a dimethyl-substituted BODIPY acceptor unit. We have demonstrated that this compound, in sub-micromolar concentrations, can effectively generate singlet oxygen in polar solvents and induce cytotoxicity in human breast cancer cells (MDA-MB-468) when exposed to light. The photophysical properties of these compounds are chemically tunable and thus open the door not only to a new class of photodynamic therapy photosensitizers, but also agents for triplet-triplet annihilation up-conversion applications.

AB - Over the past four years we have developed BODIPY dyads capable of triplet state generation from charge transfer states generated by photoinduced electron transfer. In the current work we identify a lead compound for application in photodynamic therapy. This system is composed of a phenylanthracene electron donor unit and a dimethyl-substituted BODIPY acceptor unit. We have demonstrated that this compound, in sub-micromolar concentrations, can effectively generate singlet oxygen in polar solvents and induce cytotoxicity in human breast cancer cells (MDA-MB-468) when exposed to light. The photophysical properties of these compounds are chemically tunable and thus open the door not only to a new class of photodynamic therapy photosensitizers, but also agents for triplet-triplet annihilation up-conversion applications.

KW - BODIPY

KW - Photodynamic Therapy

KW - Photosensitizer

KW - Singlet Oxygen

KW - Triplet State

UR - https://www.scopus.com/pages/publications/85075858723

U2 - 10.1117/12.2525246

DO - 10.1117/12.2525246

M3 - Conference contribution

AN - SCOPUS:85075858723

T3 - Proceedings of SPIE - The International Society for Optical Engineering

BT - 17th International Photodynamic Association World Congress

A2 - Hasan, Tayyaba

PB - SPIE

T2 - 17th International Photodynamic Association World Congress 2019

Y2 - 28 June 2019 through 4 July 2019

ER -

A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy

Abstract

Publication series

Conference

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this